Business Segments · Research and development expense
Diabetes — Research and development expense
Medtronic Diabetes — Research and development expense increased by 0.9% to $109.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.9%, from $108.00M to $109.00M.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2023
Last reportedQ1 2026
How to read this metric
Higher spending indicates a focus on future growth and innovation, though it reduces short-term operating profit.
Detailed definition
This captures the investment in innovation, clinical trials, and engineering for new diabetes management technologies an...
Peer comparison
Standard R&D expense metric used across all medical device and pharmaceutical companies.
Metric ID:
mdt_segment_diabetes_research_and_development_expenseHistorical Data
11 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $98.00M | $98.00M | $98.00M | $98.00M | $101.00M | $109.00M | $108.00M | $120.00M | $120.00M | $108.00M | $109.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +3.1% | +7.9% | -0.9% | +11.1% | +0.0% | -10.0% | +0.9% |
| YoY Change | — | — | — | — | +3.1% | +11.2% | — | — | +18.8% | -0.9% | +0.9% |
Range$98.00M – $120.00M
CAGR+4.3%
Avg YoY Growth+6.6%
Median YoY Growth+3.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Medtronic's diabetes — research and development expense?
- Medtronic (MDT) reported diabetes — research and development expense of $109.00M in Q1 2026.
- How has Medtronic's diabetes — research and development expense changed year-over-year?
- Medtronic's diabetes — research and development expense increased by 0.9% year-over-year, from $108.00M to $109.00M.
- What does diabetes — research and development expense mean?
- The amount spent on developing new diabetes products and improving existing technologies.